Growing community of inventors

Tokyo, Japan

Reimi Kawaida

Average Co-Inventor Count = 5.71

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 12

Reimi KawaidaToshinori Agatsuma (3 patents)Reimi KawaidaToshiaki Ohtsuka (3 patents)Reimi KawaidaChigusa Yoshimura (3 patents)Reimi KawaidaJun Hasegawa (2 patents)Reimi KawaidaTakako Kimura (2 patents)Reimi KawaidaTatsuji Matsuoka (2 patents)Reimi KawaidaYumi Matsui (2 patents)Reimi KawaidaAtsushi Urano (2 patents)Reimi KawaidaYasuki Kamai (2 patents)Reimi KawaidaSandra Miller (1 patent)Reimi KawaidaUlrike Schubert (1 patent)Reimi KawaidaPhilip Rodley (1 patent)Reimi KawaidaKokichi Honda (1 patent)Reimi KawaidaJun Hasegawa (1 patent)Reimi KawaidaAtsushi Urano (1 patent)Reimi KawaidaTakako Kimura (1 patent)Reimi KawaidaReimi Kawaida (4 patents)Toshinori AgatsumaToshinori Agatsuma (12 patents)Toshiaki OhtsukaToshiaki Ohtsuka (11 patents)Chigusa YoshimuraChigusa Yoshimura (5 patents)Jun HasegawaJun Hasegawa (110 patents)Takako KimuraTakako Kimura (19 patents)Tatsuji MatsuokaTatsuji Matsuoka (9 patents)Yumi MatsuiYumi Matsui (8 patents)Atsushi UranoAtsushi Urano (6 patents)Yasuki KamaiYasuki Kamai (5 patents)Sandra MillerSandra Miller (3 patents)Ulrike SchubertUlrike Schubert (3 patents)Philip RodleyPhilip Rodley (2 patents)Kokichi HondaKokichi Honda (1 patent)Jun HasegawaJun Hasegawa (3 patents)Atsushi UranoAtsushi Urano (2 patents)Takako KimuraTakako Kimura (2 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Daiichi Sankyo Company, Limited (4 from 441 patents)


4 patents:

1. 10881734 - Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof

2. 9714298 - Anti-FGFR2 antibodies and methods of use thereof for treating cancer

3. 9481733 - Anti-FGFR2 antibodies and pharmaceutical compositions thereof

4. 9403909 - Anti-MST1R antibodies and uses thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/4/2026
Loading…